Hepatitis B Virus (e.g., Hepatitis B Surface Antigen (hbsag), Pre-s Region, Hepatitis B Core Antigen (hbcag), Hepatitis B E-antigen, Dane Particle, Etc.) Patents (Class 424/227.1)
-
Publication number: 20120020998Abstract: The present invention relates to a method for inducing and amplifying specific effectors, which comprises obtaining pulsed plasmacytoid dendritic cells (pDC) by incubation of a pDC line with at least one antigen, the pulsed pDC being subsequently irradiated and brought into contact with peripheral blood mononuclear cells (PBMC), and cultured or injected into an organism. The pulsed and irradiated pDC and the PBMC share at least one major histocompatibility complex (MHC) allele.Type: ApplicationFiled: May 15, 2009Publication date: January 26, 2012Applicant: ETABLISSEMENT FRANCAIS DU SANGInventors: Joel Plumas, Caroline Aspord, Laurence Chaperot-Dubonnet
-
PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS
Publication number: 20120014989Abstract: The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.Type: ApplicationFiled: September 26, 2011Publication date: January 19, 2012Inventors: James D. Rodgers, Haisheng Wang, Andrew P. Combs, Richard B. Sparks -
Publication number: 20120003277Abstract: The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more immunogens within the oil phase of the nanoemulsion and methods of using the same for the induction of immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against an environmental pathogen)). Compositions and methods of the invention find use in, among other things, clinical (e.g., therapeutic and preventative medicine (e.g., vaccination)) and research applications.Type: ApplicationFiled: June 30, 2011Publication date: January 5, 2012Applicants: NANOBIO CORPORATION, THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: James R. Baker, JR., Tarek Hamouda, Susan M. Ciotti
-
Patent number: 8088392Abstract: The present invention provides methods for the use of viral capsid proteins and chaperone proteins to produce immunogenic macro-molecular structures as antigen carrier to carry desired epitopes or antigens, for enhancing the immunogenicity of the carried epitopes or antigens for therapeutic or prophylactic vaccination. The immunogenic macro-molecular structures may also be used for therapeutic or prophylactic vaccination.Type: GrantFiled: June 17, 2008Date of Patent: January 3, 2012Inventor: Yunxu Cao
-
Publication number: 20110293723Abstract: Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically acceptable excipient.Type: ApplicationFiled: May 26, 2011Publication date: December 1, 2011Applicant: Selecta Biosciences, Inc.Inventors: Robert L. Bratzler, Grayson B. Lipford, Lloyd Johnston, Charles Zepp
-
Publication number: 20110293658Abstract: A method of protecting a mammalian subject against, or treating, a disease, wherein the mammalian subject has elevated numbers and/or activities of MDSC comprising administering to the subject a pharmaceutically acceptable amount of an iNKT agonist, such as alpha galactosylceramide or an analogue thereof, or a TLR agonist, or a combination thereof.Type: ApplicationFiled: November 12, 2009Publication date: December 1, 2011Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.Inventors: Vincenzo Cerundolo, Carmela De Santo
-
Patent number: 8067011Abstract: The present invention provides a targeted multi-layered drug delivery system for the delivery of cytotoxic agents to B-cells.Type: GrantFiled: April 9, 2007Date of Patent: November 29, 2011Assignee: Chimeros, Inc.Inventors: Claude Geoffrey Davis, Miguel A. de los Rios, Kenneth J. Oh, Timothy L. Bullock, Patrick T. Johnson, Jacek Ostrowski
-
Patent number: 8029803Abstract: Disclosed herein are the nucleotide sequences, deduced amino acid sequences as well as methods and compositions necessary to elicit immune responses against chronic Hepatitis B infections in animals and humans. Immune response is enhanced by fusing relevant viral antigens with xenotypic immunoglobulin heavy chain region through a peptide linker and producing the fusion proteins in Baculovirus expression system to incorporate high mannose glycosylation. By virtue of the antibody component, the fusion proteins bind to Fc receptors on the surface of antigen presenting cells, are taken up, processed and derived peptides are presented on MHC Class I, which elicit a CTL (Th1) response. In a similar fashion, due to cross priming and presentation on MHC Class II, will elicit a humoral (Th2) response. In addition, disclosed are the methods of cloning, expression and production of the fusion proteins.Type: GrantFiled: February 13, 2003Date of Patent: October 4, 2011Assignee: Paladin Labs, Inc.Inventors: Rajan George, Lorne Tyrrell, Antoine Noujaim
-
Publication number: 20110236422Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: ApplicationFiled: December 23, 2010Publication date: September 29, 2011Inventors: Angeline Ingrid Bartholomeusz, Stephen Logarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus
-
Patent number: 8025887Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: GrantFiled: October 28, 2009Date of Patent: September 27, 2011Assignees: The United States of America as represented by the Department of Health and Human Services, Centers for Disease Control and Prevention, Mahidol UniversityInventors: Richard M. Kinney, Claire Y. H. Kinney, Duane J. Gubler, Siritorn Butrapet, Natth Bhamarapravati
-
Patent number: 8025873Abstract: Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular embodiments, the compounds and methods elicit immune responses against antigens that are otherwise recognized by the host as “self” antigens. The immune response is enhanced by presenting the host immune system with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises a xenotypic antibody fragment. By virtue of the target binding domain, antigen presenting cells take up, process, and present the chimeric antigen, eliciting both a humoral and cellular immune response.Type: GrantFiled: August 5, 2004Date of Patent: September 27, 2011Assignee: Paladin Labs, Inc.Inventors: Rajan George, Lorne Tyrrell, Antoine Noujaim, Dakun Wang, Allan Ma
-
Publication number: 20110223197Abstract: Mucosal and systemic administration of compositions comprising alphavirus replicon particles to induce immune responses in a subject is described.Type: ApplicationFiled: October 17, 2006Publication date: September 15, 2011Applicant: NOVARTIS VACCINES AND DIAGNOSTICS INC.Inventor: Michael Vajdy
-
Patent number: 8007805Abstract: Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular, the compounds and methods elicit immune responses against foreign antigens that are otherwise recognized by the host as “self” antigens, thus breaking host tolerance to those antigens. Presenting the host immune system with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises an antibody fragment, enhances the immune response against the foreign or tolerated antigen. Antigen presenting cells take up, process, and present the chimeric antigen, eliciting both a humoral and cellular immune response against the desired antigen.Type: GrantFiled: August 5, 2004Date of Patent: August 30, 2011Assignee: Paladin Labs, Inc.Inventors: Rajan George, Lorne Tyrrell, Antoine Noujaim, Dakun Wang, Allan Ma
-
Publication number: 20110182939Abstract: The invention provides novel adjuvants and pharmaceutical composition comprising of an adjuvant alone. The invention also provides novel vaccine compositions comprising of an antigen and a novel adjuvant. The novel adjuvant as per present invention is farnesoid-X-receptor (FXR) antagonist. The invention also relates to an adjuvant for variety of antigens. The adjuvant improves antibody production specific to incorporated antigen. The adjuvant also induces cell mediated immune response.Type: ApplicationFiled: September 26, 2009Publication date: July 28, 2011Applicant: CADILA PHARMACEUTICALS LTD.Inventors: Bakulesh Mafatlal Khamar, Ambalal Indravadan Modi, Indravadan Rajiv Modi
-
Publication number: 20110165194Abstract: The present invention relates to an HBV vaccine comprising an entire hepatitis B surface antigen of L protein, M protein and S protein, in which the produced antigens form virus-like particles, and a multi-antigen vaccine further comprising an HBV core antigen in addition to the entire surface antigen, and a method for preparing the same. The vaccines provide various epitopes and have excellent immunogenicity to induce a strong humoral immune response as well as a cell-mediated immune response.Type: ApplicationFiled: January 28, 2008Publication date: July 7, 2011Inventors: Jung Sun Yum, Byung Cheol Ahn, Hyun Jin Jo, Dong Yeon Kim, Joo Youn Lee, Ki Hyun Kim, Jae Seung Yoon, Hong Mo Moon
-
Patent number: 7964196Abstract: A self-assembling nanoparticle drug delivery system for the delivery of drugs including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the drug, a lipid bi-layer envelope and targeting or facilitating molecules anchored in the lipid bilayer. A method for construction of the self-assembling nanocparticle drug delivery system is also provided.Type: GrantFiled: May 25, 2005Date of Patent: June 21, 2011Assignee: Chimeros, Inc.Inventors: Miguel de los Rios, Kenneth J. Oh
-
Publication number: 20110129489Abstract: The present invention relates to the generation of an immune response against a target antigen using a DNA and viral vector in a specific administration pattern.Type: ApplicationFiled: July 7, 2008Publication date: June 2, 2011Inventors: Erik Depla, Annegret Van Der Aa, Sofie De Schepper, Stany Depraetere, Karen De Vreese
-
Publication number: 20110110979Abstract: The present invention relates to a method for treating an infection or disease or lesion, in particular an HPV infection. Furthermore, it relates to a vaccine for treating a Human Papillomavirus (HPV) infection or an associated disease or lesion in a subject.Type: ApplicationFiled: April 1, 2009Publication date: May 12, 2011Applicant: Universite De LausanneInventor: Denise Nardelli Haefliger
-
Publication number: 20110097362Abstract: The present invention relates to modulation of the immune response in a mammal. In particular, the invention relates to methods of inducing oral tolerance and systemic immunity in a mammal. The invention sets forth methods and compositions useful in inducing oral tolerance and systemic immunity in a mammal.Type: ApplicationFiled: October 17, 2003Publication date: April 28, 2011Inventors: Frank Michaels, Karen Dohm
-
Patent number: 7931907Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to agents and in particular nucleoside analogues. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues. The variants may also comprise corresponding mutations affecting immunological interactivity to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: October 6, 2008Date of Patent: April 26, 2011Assignees: Melbourne Health, Austin and Repatriation Medical Centre, Central Sydney Area Health ServiceInventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Margaret Rose Littlejohn, Geoffrey William McCaughan, Peter William Angus
-
Publication number: 20110091501Abstract: The invention provides rhinovirus vectors, which can be used in the delivery of immunogens, such as influenza virus immunogens, and corresponding compositions and methods.Type: ApplicationFiled: March 27, 2009Publication date: April 21, 2011Applicant: SANOFI PASTEUR BIOLOGICS CO.Inventors: Kirill Kalnin, Yanhua Yan, Maryann Giel-Moloney, Harold Kleanthous
-
Patent number: 7927601Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs or other antagonists of HBV DNA polymerase activity and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants. These assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular the resistant HBV variants of the present invention. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: September 28, 2005Date of Patent: April 19, 2011Assignees: Melbourne Health, Fundacion Investigacion y Educacion En SidaInventors: Julie Sheldon, Berta Rodes, Vincent Soriano, Angeline Ingrid Bartholomeusz
-
Patent number: 7910110Abstract: The present invention relates to vaccines comprising a bacteriophage which has been engineered to express an immunogenic protein/peptide and wherein the surface of the bacteriophage has not been modified to contain proteins/peptides designed to target the phage to receptors on the surface of specific cell types.Type: GrantFiled: October 2, 2003Date of Patent: March 22, 2011Assignee: BigDNA LimitedInventors: John Bernard March, Jason Clark
-
Publication number: 20110059132Abstract: The present invention relates to a composition, comprising: i) an HBcAg1-x, wherein x is a whole number from the range from 100 to 160, a fragment of this antigen, a variant of this antigen or of the fragment of this antigen or at least two thereof, ii) an adjuvant comprising a saponin or a saponin derivative or a mixture of at least two thereof, and optionally iii) an HBsAg, a fragment from this antigen, a variant of this antigen or of the fragment of this antigen or at least two thereof.Type: ApplicationFiled: September 16, 2006Publication date: March 10, 2011Inventors: Karl Melber, Pascale Buchmann, Zbigniew Janowicz
-
Publication number: 20110052496Abstract: Aspects of the invention provide hollow nanoparticles and uses thereof. In particular, the invention provides membrane-enclosed vesicles comprising a truncated form of an HBsAg S protein lacking one or two of its amino-terminal transmembrane domains.Type: ApplicationFiled: August 27, 2010Publication date: March 3, 2011Inventor: Angel Cid-Arregui
-
Patent number: 7887813Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: October 31, 2007Date of Patent: February 15, 2011Assignees: Melbourne Health, St. Vincent's Hospital Melbourne, Austin HealthInventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus
-
Publication number: 20110027318Abstract: Nucleotide vector composition containing such vector and vaccine for immunization against hepatitis. Nucleotide vector comprising at least one gene or one complementary DNA coding for at least a portion of a virus, and a promoter providing for the expression of such gene in muscle cells. The gene may be the S gene of the hepatitis B virus. A nucleotide vector composition when administered to even chronic HBV carriers is capable of breaking T cell tolerance to the surface antigens of hepatitis B virus. A vaccine preparation containing said bare DNA is injected into the host previously treated with a substance capable of inducing a coagulating necrosis of the muscle fibers.Type: ApplicationFiled: March 24, 2009Publication date: February 3, 2011Applicants: Institut Pasteur, Institut National de la Sante et de la Recherche MedicaleInventors: Marie-Louise Michel, Maryline Mancini
-
Publication number: 20110020397Abstract: The present invention relates to hydrophobic modified preS-derived peptides of hepatitis B virus (HBV) which are derived from a HBV preS consensus sequence and are N-terminal preferably acylated and optional C-terminal modified. These hydrophobic modified preS-derived peptides of HBV are very effective HBV entry inhibitors as well as HDV entry inhibitors and are, thus, suitable for the inhibition of HBV and/or HDV infection, prevention of primary HBV and/or HDV infection as well as treatment of (chronic) hepatitis B and/or D. The present invention further relates to pharmaceutical and vaccine compositions comprising these hydrophobic modified preS-derived peptides of HBV.Type: ApplicationFiled: January 26, 2009Publication date: January 27, 2011Applicant: UNIVERSITATSKINIKUM HEIDELBERGInventors: Walter Mier, Stephan Urban
-
Publication number: 20110014229Abstract: The invention provides chimeric flavivirus vectors including foreign peptides inserted into the envelope proteins of the vectors and methods of using these vectors.Type: ApplicationFiled: July 14, 2009Publication date: January 20, 2011Applicant: Sanofi Pasteur Biologics Co.Inventors: Harold Kleanthous, Charles Miller, Larisa Oros
-
Patent number: 7867498Abstract: The invention relates to polypeptide carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are useful as components of vaccines that can elicit a T-cell dependent immune response. These vaccines are particularly useful to confer protection against infection from encapsulated bacteria in infants between the ages of 3 months and about 2 years.Type: GrantFiled: March 25, 2009Date of Patent: January 11, 2011Assignee: Novartis AGInventors: Rino Rappuoli, Guido Grandi
-
Publication number: 20110002961Abstract: A method of treating a patient with a disease wherein the patient contains diseased cells which cells contain antigens for identification and which cells are capable of presenting at least part of said antigen on their surface by an HLA class I (or equivalent) molecule, the method comprising administering to the patient a therapeutically effective amount of either antigen presenting cells which have been gene delivered with the interleukin 12 (IL-12) gene plus a relevant antigen. In a related set of claims said method refers to the administration to a patient of therapeutic levels of cytotoxic T lymphocytes (CTL) which recognize at least part of said antigen when presented by an HLA class I (or equivalent) molecule on the surface of a cell and which these CTL were stimulated by the antigen presenting cells, mentioned in the first section, which have been gene delivered with the interleukin 12 (IL-12) gene plus a relevant antigen.Type: ApplicationFiled: March 3, 2009Publication date: January 6, 2011Inventor: Paul Hermonat Hermonat
-
Publication number: 20100316669Abstract: Formulation of vaccine antigens, containing as main components: a-) one or several DNA expressing one or several proteins in the immunized individuals and b-) a viral antigen, in appropriate proportions. Development of new formulations, minimizing the number of components that enhance and diversify the spectrum of immune response against different pathogenic entities and generating combined vaccines against pathogens. These formulations can be applied in the pharmaceutical industry for preventive and-or therapeutic use in human.Type: ApplicationFiled: April 27, 2009Publication date: December 16, 2010Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Santiago Duenas Carrera, Juan Morales Grillo, Liz Alvarez-Lajonchere Ponce de Leon, Alexis Musacchio Lasa, Rolando Pajon Feyt, Ariel Vina Rodriguez, Julio C. Alvarez Obregon, Nelson Acosta Rivero, Gillian Martinez Donato
-
Publication number: 20100313298Abstract: The described binary vector with containing the expression cassette of the S-HBsAg protein under the control of the constitutive 35S promoter as well as the method of transforming lettuce using a strain of Agrobacterium tumefaciens containing the vector, facilitate the production of plant material for the manufacture of an oral HepB vaccine.Type: ApplicationFiled: June 26, 2008Publication date: December 9, 2010Inventors: Tomasz Pniewski, Josef Kapusta, Piotr Bociag, Anna Kostrzak, Bogdan Wolko, Andrzej Plucienniczak, Grazyna Plucienniczak, Piotr Woickik, Halina Otta, Jacek Wojciechowicz
-
Publication number: 20100297170Abstract: The invention refers an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R1—XZSZN—XZX—R2 and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.Type: ApplicationFiled: April 13, 2010Publication date: November 25, 2010Inventors: Michael Buschle, André Habel, Jörg Fritz, Karin Prinz, Karen Lingnau
-
Patent number: 7838006Abstract: A composition for treating or preventing virus-induced infections is described, along with a process of producing the composition and methods of the composition's use. The composition comprises viral pathogen-infected cell or tissue, or malignantly or immunologically aberrant cells or tissues which has been reduced and/or denatured. The preferred composition is administered across a mucosal surface of an animal suffering or about suffer from infection. The composition is administered as preventive or therapeutic vaccine.Type: GrantFiled: April 14, 2008Date of Patent: November 23, 2010Assignee: Immunitor USA Inc.Inventors: Vichai Jirathitikal, Aldar Bourinbaiar
-
Publication number: 20100285060Abstract: The present invention provides methods of vaccination as well as pharmaceutical combinations and kits for enhancing vaccine effectiveness, including for immunodeficient or immunecompromised patients, including non-responders and low-responders to vaccination. As disclosed herein, the invention relates to administering a vaccine and a regimen of thymosin alpha peptide so as to provide higher antibody titers, speed the development of such antibody titers, and/or to provide for a longer duration of such antibody titers, thereby providing a greater protective effect. In another aspect, the invention allows for reducing a vaccine dose, such as an influenza vaccine dose, by administration of a thymosin peptide regimen.Type: ApplicationFiled: May 10, 2010Publication date: November 11, 2010Applicant: SciClone Pharmaceuticals, Inc.Inventor: Cynthia W. TUTHILL
-
Publication number: 20100285064Abstract: The present invention provides a Withania somnifera fraction rich in withanolides and a vaccine comprising a “Withania somnifera fraction” as an adjuvant.Type: ApplicationFiled: May 5, 2010Publication date: November 11, 2010Applicant: SERUM INSTITUTE OF INDIA LTD.Inventors: Suresh Sakharam Jadhav, Bhushan Patwardhan, Manish Gautam
-
Publication number: 20100272805Abstract: One embodiment of the current disclosure relates to an immune-modulating composition comprising a hydrogel-forming polymer, an immune-modulating biomolecule operable to recruit or retain an immune cell, and an antigen-related biomolecule. Another embodiment of the current disclosure relates to a method of providing an antigen to an antigen presenting cell in an animal by administering to the animal at an administration site an immune-modulating composition as described above. Next, one forms a hydrogel in-situ from the hydrogel-forming polymer, then recruits at least one antigen presenting cell to the administration site using the immune-modulating biomolecule, and finally inducing phagocytosis of the at least one antigen-related biomolecule by the antigen presenting cell.Type: ApplicationFiled: April 21, 2010Publication date: October 28, 2010Inventors: Ankur Singh, Krishendu Roy, Sudhir Kasturi
-
Publication number: 20100266534Abstract: The present invention relates to an adjuvant derived from human lymphocytes. The adjuvant can be used in combination with traditional vaccines or cancer immunotherapy, to enhance the response of the patient's immune system to the vaccine or other immunotherapeutic agent. The adjuvant is derived from the supernatant collected from cultured activated lymphocytes.Type: ApplicationFiled: June 28, 2010Publication date: October 21, 2010Applicants: HASUMI LLC, UNIVERSITY OF BALTIMORE, MARYLANDInventors: Kenichiro Hasumi, Dean LeMar Mann, Kim Graulich Hankey, Kristina Michelle Holt
-
Patent number: 7811576Abstract: The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.Type: GrantFiled: January 7, 2008Date of Patent: October 12, 2010Assignee: Vaccine Research Institute of San DiegoInventors: David R. Milich, Jean-Noel Billaud
-
Publication number: 20100247573Abstract: This invention provides pharmaceutical compositions, such as vaccines, and methods of making and using such compositions.Type: ApplicationFiled: November 7, 2007Publication date: September 30, 2010Applicant: SANOFI PASTEUR BIOLOGICS CO.Inventors: Daniel C. Vellom, James E. Woiszwillo, Amy Woiszwillo, Dara O'Neil, Jennifer Woiszwillo, Cole Woiszwillo, Paul DeGeorge, Peter Ciarametaro
-
Publication number: 20100239608Abstract: The present invention relates to a pharmaceutical composition containing an mRNA that is stabilised by sequence modifications in the translated region and is optimised for the translation. The pharmaceutical composition according to the invention is particularly suitable as an inoculating agent as well as a therapeutic agent for tissue regeneration. In addition a process is described for determining sequence modifications that serve for the stabilisation and translation optimisation of mRNA.Type: ApplicationFiled: May 26, 2010Publication date: September 23, 2010Applicant: CUREVAC GMBHInventors: FLORIAN VON DER MÜLBE, INGMAR HOERR, STEVE PASCOLO
-
Publication number: 20100172937Abstract: Methods for reducing infectivity by providing an enveloped virus neutralizing compound (EVNC) are provided. Methods of preparing a vaccine, vaccine formulations, and methods of immunizing a subject a further provided. Methods of disinfecting a surface are still further provided. In some embodiments, compositions comprising an isolated and purified bioactive EVNC agent are provided.Type: ApplicationFiled: May 2, 2008Publication date: July 8, 2010Inventor: Girish J. Kotwal
-
Patent number: 7744898Abstract: Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV polymerase, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens.Type: GrantFiled: September 8, 2005Date of Patent: June 29, 2010Assignee: The Scripps Research InstituteInventor: Francis V. Chisari
-
Publication number: 20100151031Abstract: The presently disclosed invention is broadly directed to therapeutic micro- and/or nanoparticles designed to target an immune cell with an active agent. More particularly, the particles have a predetermined geometry and a broadest dimension of less than about 10 ?m. The immune cell-targeted micro and/or nanoparticles may additionally comprise a biocompatible polymer.Type: ApplicationFiled: March 24, 2008Publication date: June 17, 2010Inventors: Joseph M. DeSimone, Robby Petros, Jeffrey Frelinger, Adam Buntzman
-
Publication number: 20100136043Abstract: The invention provides an immunogenic composition comprising at least one antigen in association with micropar-tides, wherein the microparticles are in the same size range as viruses. In addition the invention also provides vaccine compositions and methods of eliciting immune responses in a subject.Type: ApplicationFiled: October 21, 2009Publication date: June 3, 2010Applicant: AUSTIN RESEARCH INSTITUTEInventor: Magdalena Plebanski
-
Publication number: 20100112078Abstract: The present invention provides a vaccine composition comprising an effective amount of antigen or a nucleic acid encoding antigen, encapsulated in polymeric particles, wherein said polymeric particles comprises nanoparticles, microparticles or combinations thereof, wherein surprisingly the nanoparticle induces cellular response and the microparticle induces humoral response. The invention further provides a method of inducing cellular and/or humoral immune response.Type: ApplicationFiled: September 25, 2009Publication date: May 6, 2010Applicant: NATIONAL INSTITUTE OF IMMUNOLOGYInventors: Amulya K. Panda, Kanchan Vibhu
-
Publication number: 20100068228Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.Type: ApplicationFiled: August 5, 2009Publication date: March 18, 2010Applicant: Pharmexa Inc.Inventors: Alessandro SETTE, John Sidney, Scott Southwood, Maria Vitiello, Brian Livingston, Esteban Celis, Ralph Kubo, Howard Grey, Robert Chesnut
-
Publication number: 20100055129Abstract: Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.Type: ApplicationFiled: August 28, 2009Publication date: March 4, 2010Applicant: TAIGA BIOTECHNOLOGIES, INC.Inventors: Yosef Refaeli, Brian Curtis Turner
-
Publication number: 20100047281Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs or other antagonists of HBV DNA polymerase activity and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants. These assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular the resistant HBV variants of the present invention. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.Type: ApplicationFiled: September 28, 2005Publication date: February 25, 2010Applicants: Melbourne Health, Fundacion Investigacion Y Educacion En SidaInventors: Julie Sheldon, Berta Rodes, Vincent Soriano, Angeline Ingrid Bartholomeusz